This integrative genomic and single-cell framework identified six high-confidence druggable genes (LAMC1, TFRC, TNFSF14, PLK1, TYMS, and TSSK6) with potential therapeutic relevance in CRC. This evidence concerns the gene PLK1 and colorectal carcinoma.